A new online tool developed by researchers at the University of Exeter in the UK aims to revolutionize the treatment of type 2 diabetes by recommending the most effective medication tailored to individual patients. The tool analyzes clinical data, such as body mass index (BMI), cholesterol levels, and HbA1c, a key blood test for measuring average blood sugar levels over two to three months, to recommend the best medication for each patient.
This innovation comes at a critical time, as a recent study revealed that fewer than 18% of people with type 2 diabetes in England are prescribed the most effective medication for their condition. The tool offers a personalized approach by providing a choice between five major drug classes, including DPP-4 inhibitors, GLP-1R agonists, sulfonylureas, SGLT2 inhibitors, and thiazolidinediones, marking the first time a model like this has been introduced.
Type 2 diabetes requires careful management to prevent complications such as kidney disease and nerve damage. Despite the availability of multiple medications, their effectiveness can vary from person to person. Currently, metformin is the first-line treatment for many patients, but additional medications may be necessary. The tool, developed and tested using data from over one million patients in the UK, has shown promising results. Patients recommended medications by the model had lower HbA1c levels after 12 months, reduced risks of complications over five years, and a 38% lower risk of poor blood sugar control.
This new personalized approach is not only innovative but also cost-effective, as it uses routine clinical measures like weight, sex, and standard blood tests. Researchers believe the tool could be implemented immediately in clinical settings without incurring additional costs. The model is already being tested in 22,500 patients across Scotland, and if successful, it could improve outcomes for millions of people living with type 2 diabetes globally.
The study highlights the importance of precision medicine, which tailors treatments to individual needs. If widely adopted, this tool could become the most significant advancement in type 2 diabetes care in over a decade, greatly reducing the risks associated with the condition and easing the burden on patients.
READ MORE: